DN 016
Alternative Names: DN-016Latest Information Update: 28 May 2022
At a glance
- Originator Shanghai De Novo Pharmatech
- Class Antineoplastics; Heterocyclic compounds
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in China (PO)
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer(Combination therapy) in China (PO)
- 21 Apr 2018 Preclinical trials in Cancer (Combination therapy) in China (PO)